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Our study shows that use of invasive coronary strategy varies according to availability of 
cardiac catheterization facilities at the admitting hospital. Patients admitted to hospitals with 
diagnostic catheter laboratory are less likely to receive invasive coronary strategy. In high-risk 
NSTEMI patients, admission to diagnostic hospitals was also associated with increased odds 
of in-hospital mortality. The lower rates of invasive coronary strategy in patients admitted to 
diagnostic hospitals suggests that in clinical practice, physicians are likely to adopt a risk-
averse strategy particularly in high-risk NSTEMI patients. Future efforts are particularly 
required to develop regional pathway for uniform access to invasive coronary strategy 
particularly in high-risk NSTEMI patient. 
Abstract:  
Background: 
While previous studies report increased use of invasive coronary strategy in patients admitted 
to hospitals with onsite cardiac catheter laboratory (CCL) facilities, the utility of invasive 
coronary strategy according to types of CCL facilities at the first admitting hospital and clinical 
outcomes is unknown. 
Methods: We included 452,216 patients admitted with a diagnosis of NSTEMI in England & 
Wales between 2007-2015. The admitting hospitals were categorized into; no-laboratory, 
diagnostic and PCI hospitals according to CCL facilities. Multilevel logistic regression models 
were used to study association between CCL facilities and in-hospital outcomes. 
Results: 97,777 (21.6%) were admitted to `no laboratory` whereas 134,381 (29.7%) and 
220,058 (48.7%) patients were admitted to `diagnostic` and PCI hospitals, respectively. Use of 
coronary angiography was significantly higher in PCI hospital (77.3%) compared to 
`diagnostic` (63.2%) and `no laboratory` (61.4%) hospitals. The adjusted odds of in-hospital 
mortality were similar for `diagnostic` (OR 0.93 95%CI 0.83-1.04) and PCI hospitals (OR 1.09 
95%CI 0.96-1.24), compared to `no laboratory` hospitals. However, in high-risk NSTEMI 
(defined as GRACE score>140) subgroup, an admission to `diagnostic` hospitals was 
associated with significantly increased in-hospital mortality (OR 1.36 95%CI 1.06-1.75) 
compared to `no laboratory` and PCI hospitals.   
Conclusions:  Our study highlights important differences in both the utilisation of invasive 
coronary strategy and subsequent management/outcomes of NSTEMI patients according to 
admitting hospital CCL facilities. High-risk NSTEMI patients admitted to ‘diagnostic’ 
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hospitals had greater in-hospital mortality, possibly because of reduced PCI use, which needs 
to be addressed.  
 
Introduction:   
Invasive coronary angiography (CA) is the gold standard diagnostic modality for the 
assessment of coronary artery disease in patients admitted with acute coronary syndromes 
(ACS). Patients who present with ST-elevation acute myocardial infarction (STEMI) are 
urgently transferred for primary percutaneous coronary intervention (PCI) even when they 
initially present to hospitals without onsite cardiac catheter laboratory facilities. In contrast, the 
decision to undertake CA in patients admitted with NSTEMI is based on initial presentation, 
ECG changes, risk factors, presence of haemodynamic instability and co-existing 
comorbidities1-3. Organisational factors, such as the availability of cardiac catheter laboratory 
facilities at the presenting hospital, are important determinants of utilisation of CA and further 
management4-6.  
NSTEMI patients may be admitted to hospitals without PCI capability and in some 
cases without diagnostic catheter laboratory facilities.7-10 Previous studies have reported a 
positive association between the presence of an on-site catheter laboratory and receipt of CA 
in patients with ACS5, 6, 11-14 but the association between catheter laboratory facilities at the 
admitting hospital with clinical outcomes were inconsistent 5, 6, 11-13, 15, 16. The interpretation of 
these data is challenging because the majority of previous studies are based on mixed cohorts 
of ACS patients including STEMI as well as NSTEMI patients and the availability of 
diagnostic only and PCI capable interventional facilities, in particular, is not considered 
separately. Currently, guidelines recommend an early invasive coronary strategy within 24 
hours in NSTEMI patients presenting with high-risk features such as those with GRACE score 
>140, however, such time target times are unlikely to be met without the presence of onsite 
cardiac catheter laboratory facilities1, 2. More importantly, there is a paucity of data around the 
use of invasive coronary strategy and clinical outcomes stratified according to admitting 
hospital catheter laboratory facilities in high-risk NSTEMI patients such as those with GRACE 
risk score >140. As such, it remains unclear how the types of cardiac catheter laboratory 
facilities at the first admitting hospital might influence the utilisation of invasive coronary 
strategy in the form of CA or PCI and outcomes of patients with NSTEMI.  
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The main aim of the present study was to describe associations between use of invasive 
coronary strategy and outcomes in patients with NSTEMI and how these associations are 
influenced by the catheter laboratory and interventional (PCI) facilities of admitting hospitals. 
In order to further delineate the association between baseline NSTEMI risk and clinical 
outcomes, we also undertook a pre-specified subgroup analysis of high-risk patients with a 
GRACE score >140.  
Methods:  
Study Design: 
The Myocardial Ischemia National Audit Project (MINAP) is a national audit which 
prospectively collects information around the management of ACS in England and Wales to 
meet the audit requirements of National Service Framework (NSF) for coronary heart disease17-
19. Data are collected prospectively at each hospital, electronically encrypted, and transferred 
online to a central database. MINAP amasses almost 85,000 hospital admissions per year with 
a diagnosis of ACS admitted to acute National Health Service (NHS) hospitals in England and 
Wales20. Each entry in the MINAP dataset provides comprehensive information about patient’s 
journey encompassing patient demographics, coexisting comorbidities, admission 
method/route, clinical characteristics and investigations, in-hospital drug treatments, primary 
reperfusion treatment, interventional treatments, in-hospital outcome, diagnosis on discharge 
and discharge (secondary prevention) treatment21-23.   
Study population:  
The analytic cohort for this study included all patients over the age of 18 years, admitted with 
a diagnosis of NSTEMI in one of the 235 hospitals in the England and Wales from 1st Jan 2007 
and 31st Dec 2015. We only included the first admission of each patient in the dataset which 
was then matched to the first admitting hospital catheter laboratory facilities at the time of 
admission to minimize the influence of changing status of cardiac catheter laboratory facilities 
over time. The discharge diagnosis of NSTEMI was determined by local clinicians according 
to presenting history, clinical examination, and the results of inpatient investigations in keeping 
with the consensus document of the Joint European Society of Cardiology and American 
College of Cardiology24. Patients with missing age, gender, and in-hospital mortality 
information were excluded from the analysis (Supplementary Figure S1).  All patients were 
stratified into three groups; according to the catheter laboratory facilities of the admitting 
hospital as follows:  `no lab` hospitals – hospital without catheter laboratory; `diagnostic` 
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hospitals – hospitals with diagnostic catheter laboratory only; PCI hospitals – hospital with 
interventional laboratory facilities. We collected information on the patient’s baseline 
characteristics, details of the presentation, comorbidities, in-hospital and discharge 
pharmacology, receipt of invasive strategies during admission and GRACE score. GRACE 2.0 
score was calculated as previously described25 and patients were categorised into low (<109), 
intermediate (109-140) and high-risk (>140) categories as per international guidelines1, 2. The 
outcomes of interest were in-hospital all-cause mortality, cardiac mortality, and major 
bleeding. The in-hospital major bleeding in MINAP is defined as a composite of intracranial 
bleeding, retroperitoneal bleeding, any bleed with Hb fall > 50g or any bleed with Hb fall > 
30g and < 50g or any bleed with Hb fall <30 g.  We also examined the association between the 
presence of cardiac catheter laboratory facilities and in-hospital clinical outcomes in high-risk 
NSTEMI patients defined as GRACE>140 as a complete case analysis. In order to further 
delineate the differences in treatment practices of high-risk NSTEMI patients admitted first in 
diagnostic hospitals, we performed a sensitivity analysis of patients receiving CA onsite at the 
diagnostic hospitals compared to those transferred out directly to PCI hospitals from the 
diagnostic hospitals for CA.  
Ethical approval 
The MINAP database is collected and used for research purposes without informed patient 
consent by the National Institute for Cardiovascular Outcomes Research (NICOR) under 
section 251 of the National Health Service Act 2006. Therefore, ethical approval was not 
required for this study under current arrangements by the National Health Service research 
governance.  
Statistical analysis 
The baseline characteristics across the three groups were described using the number and 
percentages for categorical variables and median and interquartile ranges for continuous 
variables. In order to limit the influence of biases related to missing data, we used multiple 
imputation techniques with chained equations to account for the missing data. Age, gender, 
hospital catheter laboratory status, ethnicity and in-hospital all-cause and cardiac mortality 
were registered as regular variables in the imputations model whereas all other variables 
including body mass index (BMI), GRACE risk score, seen by cardiologists, left ventricular 
(LV) systolic function, ECG changes defined as ST depression or transient ST elevation or T 
wave inversion, prior history of PCI, coronary artery bypass graft (CABG), heart failure, 
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hypercholesterolemia, angina, cerebrovascular disease, peripheral vascular disease, chronic 
renal failure, diabetes, hypertension, smoking status, asthma/COPD, family history of coronary 
disease, in-hospital use of low molecular weight heparin, warfarin, loop diuretics, glycoprotein 
2b3a inhibitors, discharge medications including aspirin, P2Y12 inhibitors, statin, ACE 
inhibitor, beta-blocker, in-hospital major bleeding, receipt of coronary angiography and receipt 
of PCI were imputed. The variable selection in the model was based on the previous studies 
using MINAP registry and prior clinical knowledge. Using these models, 10 imputed datasets 
were generated which were used to perform all the analyses. Multivariable logistic regression 
models were used to study the independent predictors of the receipt of invasive procedures. In 
order to account for the nested structure of the data, patients within hospital sites, multilevel 
logistic regression models were fitted. Thus, a random intercept for hospital sites was used. In 
terms of the information on cardiac catheter lab facilities, this was categorized into “no lab, 
diagnostic hospitals and PCI hospital” and modelled as a fixed effect in the models. The 
multilevel logistic regression model captures any unobserved hospital components and hospital 
factors that were omitted but may influence the outcomes. All models included the same 
aforementioned variables used in the multiple imputation models as well as the year of 
admission.  Estimates in the form of odds ratios and 95% confidence intervals were reported 
and statistical significance was considered with an alpha of 0.05 in all the two-sided tests used. 
Stata college station version 14.1 was used to perform all the analyses.  
Results: 
Patient characteristics 
The analytical cohort consisted of 452,216 patients admitted with a final diagnosis of 
NSTEMI across 235 acute hospitals in England and Wales between January 1, 2007, and 
December 31, 2015 (supplementary Figure S1). 97,777 patients (21.6%) were admitted to `no 
lab` hospitals, 134,381 (29.7%) to `diagnostic` hospitals and 220,058 (48.7%) to PCI capable 
hospitals. Table 1shows the baseline characteristics of the patients stratified into three groups 
according to cardiac catheter laboratory facilities. Typically, patients admitted to PCI capable 
hospitals were younger [median age 72 interquartile range (60.8-81)], had worse baseline 
cardiovascular profiles with increased prevalence of hypercholesterolemia (39.9%), peripheral 
vascular disease (5.8%), current smoking (22.4%) and family history of coronary heart disease 
(32.1%) compared to those patients admitted to `no lab` and `diagnostic` hospitals. Higher 
proportions of patients admitted to ‘no lab’ (59.6%) and ‘diagnostic’ hospitals (58.9%) were 
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high-risk (defined as GRACE risk score >140) compared to PCI hospitals (53.4%).  Rates of 
CA were higher in PCI capable hospitals (77.3%) compared with `diagnostic` and `no lab` 
(63.2% and 61.4%) hospitals respectively. Likewise, patients in PCI capable hospitals were 
almost twice as likely to receive PCI (45.9%) compared to `no lab` (28.3%) and `diagnostic` 
hospitals (22.4%).  Higher proportions of patients (59.6%) admitted to `no lab` hospitals were 
in high-risk NSTEMI category compared to PCI capable hospitals (53.4%) and diagnostic 
hospitals (58.9%).  Patients admitted to hospitals with `no lab` facilities were less likely to be 
seen by a cardiologist (87.6%) compared with those admitted to PCI capable hospitals (95.6%) 
and diagnostic hospitals (90.9%) 
Characteristics of patients receiving coronary angiography  
Among patients receiving coronary angiography, patients admitted to PCI capable 
hospitals were more likely to be older, male and have electrographic changes on admission. 
There were no differences in baseline risk as defined by the GRACE scores across the three 
groups (Supplementary Table S2). Patients receiving coronary angiography with high-risk 
features such as those with high GRACE score, out of hospital cardiac arrest or electrographic 
changes on admission were more likely to be medically managed in if first admitted to `no lab` 
hospitals compared to `diagnostic` and PCI capable hospitals (Supplementary table S3). 
Review of high-risk patients receiving CA, by a consultant cardiologist, was also less likely in 
the 'no lab' hospitals compared with’ diagnostic’ or ‘PCI capable’ hospitals 
Characteristics of high-risk NSTEMI patients 
 In the sensitivity analysis looking at the utilisation of invasive coronary strategy and 
clinical outcomes in 100,898 high-risk NSTEMI patients (defined as GRACE score >140) 
21,226 (21.0%) were admitted to `no lab` hospitals, whereas 24,448 (24.3%) and 55,224 
(54.7%) to `diagnostic` and PCI capable hospitals respectively (Supplementary table S4). Out 
of the 24,448 admitted to `diagnostic` hospitals, 5,184 (21.2%) were transferred out to the 
nearest PCI hospital for an invasive coronary strategy in the form of CA or PCI, whereas 19,264 
(78.8%) were managed onsite at the first admitted diagnostic hospital. In this high-risk 
NSTEMI sub-cohort (GRACE score>140) admitted to diagnostic hospitals only, patients 
transferred out to a PCI capable hospital displayed a significantly worse baseline 
cardiovascular profile with increased prevalence of out of hospital cardiac arrest, 
electrographic changes, history of previous PCI or CABG, hypertension and current smoking 
status compared to those that remained and were managed in the diagnostic hospital. However, 
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the high-risk patients who are treated onsite in `diagnostic` hospitals had a higher prevalence 
of non-cardiac comorbidities such as chronic renal failure, asthma or COPD, previous 
cerebrovascular accident and peripheral vascular disease compared to those transferred to PCI 
hospitals for invasive coronary strategy.  
Temporal trends 
In the whole NSTEMI cohort, overall rates of CA increased from 50.8% to 86.0% 
during the study period while the number of PCI hospitals increased from 87 to 99 
(Supplementary Figures S2, S3). Utilisation of CA also increased in patients admitted across 
all the hospitals and by 2015 were similar in `no lab`, `diagnostic` and PCI hospitals (86.4%, 
86.0% and 85. 6%) (Figure 1a). However, although receipt of PCI also increased in patients 
across all hospitals during the study period it remained consistently lower (36.2%) in patients 
admitted to `diagnostic` hospitals compared to patients admitted to PCI hospitals (55.1%) and 
by 2015, was also lower compared to patients admitted to `no lab` hospitals (45.9%) (Figure 
1b). A similar pattern was seen for receipt of any revascularisation (composite of PCI or 
CABG) procedures in the patients admitted to `diagnostic` hospitals where receipt of any 
revascularisation procedure was 43.3% in diagnostic hospital patients compared to no lab 
(53.1%) and PCI hospitals (62.5%) patients (Figure 1c). A similar trend was observed in the 
use of revascularisation procedures in the form of PCI, CABG or any revascularisation in the 
overall cohort, in subgroup of patients receiving coronary angiography and high-risk (GARCE 
score >140) subgroup when stratified according hospital catheter laboratory facilities. For 
instance, overall receipt of CABG was 5.3% in diagnostic hospitals compared to 5.4% in lab 
and 7.1% in PCI hospital respectively.  (Supplementary Figures S4-S6). Finally, there was a 
steady decline in the in-hospital mortality and bleeding complications across all hospitals, 
however PCI hospitals had the lowest mortality and higher bleeding complications 
(Supplementary Figures S7-S8)  
Independent predictors of receipt of CA and PCI  
Independent predictors of receipt of CA and PCI in the overall cohort are reported in 
Table 2. Overall, high-risk NSTEMI patients defined by GRACE score >140 were less likely 
to receive CA (OR 0.89 95%CI 0.83-0.95) or PCI (OR 0.88 95%CI 0.84-0.94). Compared to 
patients treated in `no lab` hospitals, the odds of receiving CA were 14% higher in the 
`diagnostic` hospitals (OR 1.14 95%CI 1.11-1.16) and 64% higher in PCI hospitals (OR 1.64 
95%CI 1.60-1.68). Conversely, the odds of receiving PCI were lower in `diagnostic` hospitals 
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(OR 0.88 95%CI 0.86-0.90) but higher in PCI hospitals (OR 1.69 95%CI 1.66-1.73) compared 
to `no lab` hospitals.  
Clinical outcomes  
Supplementary Figure 3 illustrates unadjusted in-hospital outcomes stratified according 
to admission to the `no lab`, `diagnostic` and PCI hospitals respectively. In-hospital mortality 
was lowest (10.5%) in PCI hospitals compared with `diagnostic` (12.0%) and `no lab` (12.6%) 
hospitals. After adjustment for differences in baseline clinical characteristics, no differences in 
hospital mortality, cardiac mortality or bleeding complications were observed by type of 
hospitals in the overall cohort.  
Among the high-risk NSTEMI patients with a GRACE score > 140, the odds of in-hospital all-
cause mortality (OR 1.36 95% 1.06-1.75) and cardiac mortality (OR 1.28 95%CI 0.99-1.65) 
were higher in `diagnostic` hospitals compared to PCI hospitals and `no lab` hospitals 
(reference group). (Table 3). In the subgroup analysis of high-risk NSTEMI cohort admitted to 
diagnostic hospital and then either managed onsite or transferred out to PCI hospital for further 
invasive management, patients from diagnostic hospitals receiving CA onsite at the admitting 
hospital had a significant increase in in-hospital mortality (OR 1.45 95%CI 1.13-1.87) and 
cardiac mortality (1.35 95%CI 1.05-1.75) whereas patients who were admitted to ‘diagnostic’ 
hospital and then transferred out to nearest PCI hospital directly had significant reduced odds 
of all-cause mortality (OR 0.35 95%CI 0.21-0.51) and cardiac mortality (OR 0.40 95%CI 0.24-
0.65) compared to patients admitted to PCI hospitals or ‘no lab’ hospitals (reference group). 
(Table 4, Figure 2).  
Discussion:  
In this national analysis of patients admitted with a diagnosis of NSTEMI in England 
and Wales, patients admitted to hospitals with onsite cardiac catheter laboratory facilities have 
similar outcomes compared to those admitted at hospitals without such facilities. In high-risk 
NSTEMI patients (with GRACE score >140), admission to a diagnostic hospital was associated 
with an increased risk of in-hospital all-cause and cardiac mortality. This mortality hazard was 
even more pronounced in the high-risk NSTEMI subgroup who were admitted to diagnostic 
hospital and received coronary angiography locally compared to those transferred to the nearest 
PCI hospital from diagnostic hospitals. Our analysis suggests that the presence of onsite 
catheter laboratory facilities was associated with increased utilisation of invasive coronary 
angiography, although paradoxically patients admitted to diagnostic hospitals were less likely 
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to receive PCI or CABG compared to hospitals without onsite catheter laboratory facilities or 
PCI hospitals. These findings have important implications in developing regional treatment 
pathways for NSTEMI care to allow effective access to invasive coronary strategy. 
Several studies have reported the influence of on-site catheter laboratory facilities on 
invasive coronary strategy in ACS patients6, 13, 15, 16, 26-29. Unsurprisingly, the majority of these 
studies show increased use of invasive coronary strategy in patients admitted to hospitals with 
onsite cardiac catheter laboratory facilities. There are no data studying the relationship between 
the type of catheter laboratory facilities of the admitting hospital and receipt of invasive 
coronary strategy in an exclusively NSTEMI national cohort. The referral patterns and 
utilisation of invasive coronary strategy are likely to be different in NSTEMI patients, 
compared to STEMI patients where referral pathways are focussed on transfer to a PCI capable 
hospital for primary PCI and early reperfusion. In our study, we observed a uniform uptake in 
the overall use of CA in patients admitted with a diagnosis of NSTEMI in England and Wales 
independent of catheter laboratory facilities of the admitting hospital, however, patients 
admitted to diagnostic hospitals were less likely to receive invasive coronary strategy in the 
form of PCI or CABG. This is likely to be due to selection bias and variation in referral patterns 
of the admitting hospital, as patients admitted to hospitals without any laboratory facilities are 
likely to be referred to a nearest tertiary hospitals with onsite PCI facilities30. In contrast, 
patients admitted to diagnostic hospitals receive CA locally before a decision about further 
revascularisation is made by the treating physician, who may not necessarily be an 
interventional cardiologist. Consequently, such patients may be potentially denied early access 
to guideline recommended invasive coronary strategies1, 2. The lower rates of PCI and CABG 
in patients admitted to diagnostic hospitals suggests that in clinical practice, physicians are 
likely to adopt a risk-averse strategy even after obtaining information from CA particularly in 
patients admitted first to diagnostic hospitals.    
In this prospective observational cohort study of over 450,000 patients, we did not 
observe any difference in in-hospital all-cause and cardiac mortality or bleeding complications 
from an NSTEMI and type of catheter laboratory facilities at the first admitting hospital. The 
effect of onsite site versus off site cardiac catheter laboratory facilities in ACS patients was 
compared in the GRACE registry showing that patients admitted to hospital with onsite cardiac 
catheter laboratory facilities had similar outcomes as compared to those admitted to hospital 
without such facilities16. Similar findings were reported by the European Network of Acute 
Coronary Treatment (ENACT) and National Registry of Myocardial Infarction investigators 
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showing no benefit of onsite cardiac catheter laboratory facilities in ACS31, 32. To the best of 
our knowledge, this is the first study comparing association with different levels of hospital 
cardiac catheter laboratory facilities and clinical outcomes in an exclusive NSTEMI cohort. 
Our findings also highlight important differences in institutional practices and treatment gaps, 
particularly in high-risk NSTEMI patients. In the high-risk NSTEMI cohort, patients admitted 
to diagnostic hospitals first were at increased risk of in-hospital all-cause and cardiac mortality, 
which may be related to a significantly lower use of invasive coronary strategies in the form of 
PCI or CABG in these hospitals. We observed a similar mortality hazard in high-risk NSTEMI 
patient receiving CA onsite in diagnostic hospitals compared to those referred for CA to PCI 
hospitals from the diagnostic hospitals. Previous studies from international registries have 
shown that the use of invasive coronary strategies is independently associated with improved 
survival in NSTEMI patients21, 33. Ideally, hospitals treating these patients should be able to 
offer effective care and uniform access to CA and revascularisation as per guidelines 
recommendations. Therefore, regionalisation of care for NSTEMI patients whereby merging 
the diagnostic hospitals with PCI hospitals and direct referral of patients to PCI hospitals after 
appropriate risk stratification may translate into early, uniform access to invasive coronary 
strategy, better resource allocation and improved patient care26, 34. 
Current guidelines emphasize on an early invasive approach followed by revascularisation 
either in the form of PCI or CABG in patients with GRACE score ≥140 or other high-risk 
features1, 2. Our results indicate that patients presenting with high-risk features such as those 
with LV dysfunction, heart failure, history of diabetes and high GRACE score ≥140 were least 
likely to receive CA or PCI independent of the type of admitting hospitals. This finding is 
consistent with well-known treatment risk paradox whereby patient who mostly likely to 
benefit from an intervention are least likely to receive it35, 36. A recent individual patients’ level 
meta-analysis of eight RCTs including 5,324 patients found significantly lower mortality in 
high-risk patients such those with history of diabetes, age above 75 years and GRACE score ≥ 
140 when treated with early invasive strategy37. Appropriate risk stratification, recognition of 
this paradox and development of quality improvement programmes are required to offer 
guidelines recommended treatment to patients presenting with high-risk features.  
Our analysis is subject to certain limitations that should be borne in mind whilst interpreting 
these findings. We do not have follow up data beyond hospital discharge so only in-hospital 
outcomes were evaluated. However, previous studies have reported similar comparable 
outcomes at shorter and longer term follow up in patients who were admitted to hospitals with 
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or without cardiac catheter laboratory facilities in all ACS patients6, 13. Although completion 
of mandatory data fields has improved considerably in MINAP over time, there was a 
significant amount of missing data in important variables such as GRACE risk score that could 
have biased the estimates. However, in order to limit the influence of bias from missing data 
we implemented an imputation strategy as previously described and validated for use in this 
registry38. MINAP registry does not further define the types of different P2Y12 inhibitors 
(ticagelor, prasugrel) use, rather all antiplatelet information is recorded under variable “P2Y12 
inhibitor use”. Furthermore, use of anticoagulant agent information is also limited to warfarin 
in the dataset and the information around use of direct oral anticoagulants (DOACs) is not 
collected. Therefore, although we adjusted for use pf P2Y12 inhibitors on the outcomes, we 
were not able to adjust for different types of P2Y12 inhibitors and DOACs.  Finally, the 
observational nature of the study is susceptible to unmeasured confounding and only 
associations rather than causal relationships can be inferred.  
Conclusion: 
In this large, contemporary analysis from a national healthcare system, we report significant 
disparities in utilisation of invasive coronary strategy, which is influenced by the type of 
cardiac catheter laboratory facilities of the admitting hospital. Our study serves to highlight 
important differences in institutional practices and treatment gaps whereby high-risk NSTEMI 
patients admitted to diagnostic hospitals were less likely to receive invasive coronary strategy 
in the form of PCI or CABG and were at increased risk of in-hospital mortality. These 
differences in the care of NSTEMI may be improved by developing a stronger network of a 
regional system of care with transfer algorithms and implementation of guidelines directed 
invasive strategies for high-risk NSTEMI patients.  
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Table 1: Baseline characteristics of the patients stratified according to `no lab`, `diagnostic` and PCI 
hospitals.  








Age 74 [63-83] 74 [63-83] 72 [60.8-81] <0.001 
Male (%) 60,422(61.8%) 82,210 (61.2%) 144,096 (65.5%) <0.001 
Caucasians (%) 82,809 (84.7) 118,426 (88.2%) 179,008 (81.4%) <0.001 
BMI median [IQR] 27.0 [23.8-30.7] 26.9 [23.9-30.6] 27.2 [24.2-30.7] 0.0001 
Presenting Characteristics     
Heart rate, bpm, median (IQR) 80 [67-94] 80 [67-94] 77 [65-91] <0.001 
Systolic blood pressure, median (IQR) 140 [121-158] 139 [121-158] 140 [121-158] 0.001 
ECG changes 75,885 (79.6%) 104,960 (80.1%) 169,050 (78.6%) 0.001 
Trop positive 88,066 (92.5%) 122,484 (94.1%) 196,414 (91.8%) 0.001 
Out of hospital cardiac arrest 1,105 (1.2%) 1,175 (0.9%) 2,285 (1.1%) <0.001 
Creatinine, median (IQR) 93 [77-119] 94 [77-118] 90 [74-114] <0.001 
Seen by cardiologist 79,522 (87.6%) 111,775 (90.9%) 202,235 (95.6%) <0.001 
LV systolic function    <0.001 
Good 21,533 (58.2%) 29,450 (59.3%) 56,750 (60.4%)  
Moderate 10,438 (28.2%) 13,975(28.2%) 26,380(28.1%)  
Poor 5,002 (13.6%) 6,202 (12.5%) 10,836 (11.5%)  
GRACE risk score    <0.001 
Low <109 6,120(17.2%) 7,178 (17.3%) 20,742 (20.1%)  
Intermediate 109-140 8,251 (23.2%) 9,863 (23.8%) 27,351 (26.5%)  
High >140 21,226 (59.6%) 24,448 (58.9%) 55,224 (53.4%)  
Previous medical history     
Percutaneous coronary intervention 11,527(12.4%) 14,559(11.8%) 35,519 (16.6%) <0.001 
Coronary artery bypass graft 8,149 (8.7%) 11,352 (9.2%) 21,248 (10.2%) <0.001 
Heart failure 8,711 (9.3%) 10,930 (8.8%) 14,659 (7.1%) 0.001 
Hypercholesterolemia 30,475 (33.2%) 44,900(36.4%) 82,128 (39.9%) <0.001 
Angina 34,059 (36.5%) 48,243(38.9%) 69,637 (33.5%) 0.001 
Cerebrovascular disease 10,594 (11.1%) 13,771 (11.1%) 20,469 (9.8%) <0.001 
Peripheral vascular disease 4,980 (5.4%) 6,714 (5.5%) 11,758 (5.8%) <0.001 
Chronic renal failure  8,013 (8.6%) 10,100 (8.2%) 17,375 (8.4%) 0.04 
Diabetes 24,212 (25.3%) 32,395 (24.6%) 56,291 (26.1%) 0.001 
Hypertension 51,125 (54.6%) 67,945 (54.3%) 119,921 (57.0%) 0.001 
Smoking status    <0.001 
Previous smoker 36,946 (39.6%) 48,324 (38.3%) 78,747 (38.0%)  
Current smoker 18,941 (20.9%) 26,136 (20.8%) 46,456 (22.4%)  
Asthma / COPD 16,738 (18.0%) 23,049 (18.8%) 33,638 (16.3%) 0.001 
Family history of CHD 20,315 (27.4%) 27,909 (27.6%) 57,252 (32.1%) <0.001 
In-hospital Pharmacology     
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Low molecular weight heparin 58,058(64.3%) 77,468 (64.4%) 109,781 (57.2%) <0.001 
Warfarin 6,105 (6.9%) 8,649 (7.3%) 11,215 (6.1%) <0.001 
Loop Diuretic 28,666 (32.0%) 38,048 (32.1%) 52,755 (28.7%) <0.001 
Glycoprotein use 2,098 (2.3%) 2,554 (2.2%) 11,067 (5.9%) <0.001 
Coronary angiography 49,755 (61.4%) 72,277 (63.2%) 153,668 (77.3%) <0.001 
Discharge Medications     
Aspirin 61,470 (89.9%) 83,883 (89.0%) 181,828 (94.7%) <0.001 
P2Y12 inhibitors 82,895 (86.3%) 112,105 (84.9%) 192,776 (90.0%) <0.001 
Statins 61,600 (91.9%) 85,890 (91.8%) 178,985 (94.4%) <0.001 
ACE inhibitors 52,967 (80.8%) 71,151 (77.6%) 154,188 (83.9%) <0.001 





Table 2: Independent predictors of receipt of coronary angiography and percutaneous coronary 
intervention in the overall cohort 
 Predictors of receipt of 
CA 
Predictors of receipt of 
PCI 
Variables OR (95% CI) OR (95% CI) 
Grace risk Score ( low risk 
baseline) 
  
Intermediate (109-140) 1.17 (1.12-1.23) 1.09 (1.06-1.13) 
High (>140) 0.89 (0.83-0.95) 0.88 (0.84-0.94) 
Female Gender 0.73 (0.71-0.74) 0.76 (0.75-0.77) 
Age  0.94 (0.944-0.946) 0.97 (0.978-0.981) 
Previous acute myocardial infarction 0.65 (0.63-0.66) 0.70 (0.69-0.72) 
Previous coronary artery bypass 
grafting 
0.92 (0.89-0.95) 0.99 (0.96-1.02) 
Previous percutaneous coronary 
intervention 
1.28 (1.24-1.32) 1.36 (1.32-1.40) 
History of angina 0.86 (0.84-0.88) 0.86 (0.84-0.88) 
Hypertension  1.07 (1.05-1.08) 0.99 (0.97-1.07) 
Hypercholesterolemia  1.24 (1.22-1.26) 1.26 (1.23-1.28) 
Peripheral vascular disease 0.96  (0.92-0.96) 1.03 (0.99-1.07) 
Asthma/ COPD 0.94 (0.92-0.96) 0.99 (0.97-1.01) 
Chronic renal failure 0.73 (0.70-0.76) 0.88 (0.85-0.91) 
Heart failure 0.70 (0.68-0.73) 0.82 (0.79-0.85) 
Cerebrovascular accident 0.67 (0.65-0.68) 0.75 (0.73-0.77) 
Diabetes 0.84 (0.83-0.86) 0.86 (0.84-0.88) 
Left ventricular dysfunction    
Moderate  0.86 (0.83-0.89) 0.94 (0.92-0.96) 
Severe  0.67 (0.64 -0.70) 0.71 (0.68-0.74) 
Family history of coronary heart 
disease 
1.33 (1.30-1.36) 1.23 (1.21-1.25) 
Seen by cardiologist  6.09 (5.79-6.41) 4.27 (4.01-4.55) 
Catheter laboratory facilities (ref=no 
lab) 
  
Diagnostic hospitals 1.14 (1.11-1.16) 0.88 (0.86-0.90) 





Table 3:  Adjusted in-hospital clinical outcomes and different level of cardiac  
      catheter laboratory facilities 
Clinical outcomes 
Ref ( no lab centres) 
PCI hospitals Diagnostic hospitals 
In hospital death 1.09  (0.96-1.24)p=0.17 0.93 (0.83-1.04)p=0.22 
Cardiac mortality  1.03 (0.90-1.18)p=0.61 0.95 (0.84-1.07)p=0.43 
Bleeding  0.95 (0.73-1.23), p=0.70 0.99 (0.77-1.26),p=0.95 
Clinical outcomes in patients with GRACE  score >140 
In hospital death 1.10  (0.87-1.39)p=0.38 1.36 (1.06-1.75)p=0.01 
Cardiac mortality  0.94 (0.75-1.18)p=0.62 1.28 (0.99-1.65)p=0.05 
Bleeding  0.62 (0.37-1.03), p=0.06 0.96 (0.65-1.43),p=0.87 
 
Table 4: Clinical outcomes in patients with high GRACE risk score > 140 and in-hospital 
clinical outcomes. 
Clinical outcomes  






In-hospital mortality  0.35 (0.21-0.51) 1.45 (1.13-1.87) 1.06 (0.84-1.33) 
Cardiac Mortality  0.40 (0.24-0.65) 1.35 (1.05-1.75) 0.90 (0.72-1.14) 






1A: Receipt of invasive coronary angiography stratified according to hospital cardiac catheter 
laboratory facilities in England and Wales from January 1,2007 to December 31,2015 
 
CA= coronary angiography  
1B: Receipt of percutaneous coronary intervention stratified according to hospital cardiac 
catheter laboratory facilities in England and Wales from January 1,2007 to December 
31,2015 
 
PCI= percutaneous coronary intervention  
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1C: Receipt of any revascularisation procedure stratified according to hospital cardiac 
catheter laboratory facilities in England and Wales from January 1,2007 to December 
31,2015 
 
PCI= percutaneous coronary intervention, CABG= coronary artery bypass graft surgery 
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